AstraZeneca Plc (NASDAQ: AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations.
Datopotamab deruxtecan is jointly developed by Daiichi Sankyo (OTC: DSKNY) and AstraZeneca.
The interim analysis demonstrated an overall response rate in the overall population of 37% in patients receiving datopotamab deruxtecan plus Merck & Co Inc's Keytruda (pembrolizumab) (doublet therapy).
The data showed an ORR of 41% in patients receiving datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy (triplet therapy).
A disease control rate (DCR) of 84% was seen with doublet and triplet combination therapy.
In previously untreated patients, ORRs of 62% (on doublet therapy) and 50% (on triplet therapy) were observed.
Eight partial responses (PRs) were seen in patients receiving doublet therapy, and 10 PRs (three pending confirmation) were seen in patients receiving triplet therapy.
A DCR of 100% was observed with doublet therapy and 90% with triplet therapy.
Price Action: AZN shares are up 0.81% at $65.65 during the premarket session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.